Results 81 to 90 of about 31,308 (159)

The role and mechanism of IL‑35 in myasthenia gravis (Review). [PDF]

Int J Mol Med
Mao J, Zhang LM, Zhu YL, Gao SJ, Liu MW.
europepmc   +1 more source

Myasthenia Gravis [PDF]

Postgraduate Medical Journal, 1965
openaire   +2 more sources

Efficacy and safety of efgartigimod in very-late-onset myasthenia gravis. [PDF]

Front Immunol
Zhao Y, Qu M, Rong X, Sun X, Wang L, Liu M, Sui J.   +6 more
europepmc   +1 more source

Untargeted serum metabolomic profiling in patients with generalized and ocular myasthenia gravis. [PDF]

BMC Ophthalmol
Wei B, Yuan H, He J, Hu Y, Li J, Wu X.
europepmc   +1 more source

Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg. [PDF]

Neurol Ther
D'Amico F, Campo S, Rini N, Vinciguerra C, Bevilacqua L, Erra C, Barone P, Tuccillo F, Habetswallner F, Brighina F, Di Stefano V.   +10 more
europepmc   +1 more source

Comparative study of ocular and generalized myasthenia gravis in a South Korean cohort. [PDF]

PLoS One
Kwon C, Oh J, Shin HJ.
europepmc   +1 more source

IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology. [PDF]

Brain
Masi G, Chen K, Bayer AC, Bayarri-Olmos R, Pham MC, Wallace A, Falso S, Evoli A, Iorio R, Hoehn KB, Iwasaki A, Nowak RJ, O'Connor KC.   +12 more
europepmc   +1 more source

Myasthenia Gravis [PDF]

BMJ, 1963
openaire   +2 more sources

Myasthenia gravis and pregnancy: a systematic review and meta-analysis. [PDF]

J Neurol
Miegel L, Hickstein J, Reibelt A, Heesen C, Schubert C.   +4 more
europepmc   +1 more source